All updated as on -
From 2024 to 2031, the crizotinib market is expected to increase at a CAGR of 7.6%. In 2024, the market is predicted to reach 970.68 million USD, up from 923.18 million USD in 2023. By 2031, the market is expected to be worth 1,505.19 million USD.
For the treatment of non-small cell lung cancer (NSCLC), clinicians often prescribe crizotinib, a cancer drug. Because it inhibits the proliferation of tumor cells, this medication reduces the progression of cancer. Because it inhibits the proliferation of cancer cells, the medicine crizotinib is also known as an antineoplastic agent. Ultimately, the body eliminates these cancer cells. One class of targeted therapeutic medications called cancer growth inhibitors includes this substance, which is a tyrosine kinase receptor inhibitor. If the NSCLC exhibits alterations in a gene arrangement known as ALK-positive and ROS1-positive, it can be utilized. Cristopinib also prevents the proliferation of harmful cancer cells by preventing the expression of genes that code for malignancy.
Crisetinib is a medication that fights cancer. Patients with persistent non-small cell lung cancer can now take this medication thanks to the approval of the US regulatory agency. By inhibiting the proliferation of harmful cancer cells, crizotinib aims to halt the progression of deadly diseases. Inhibiting cancerous gene rearrangement is the primary goal of this drug's administration to patients, rather than providing a full cure. As long as crizotinib is effective and the medication is not causing any undesirable side effects, it is often administered at home according to a doctor's prescription. One major element propelling crizotinib's global market expansion is the drug's superior efficacy in treating non-small cell lung cancer.
This Crizotinib market research report analyzes the industry's size, sales, demand, growth, gross profit, and profitability in great detail. Using an analysis of the collected data, it predicts what might happen in the industry over the next several years. This study used 2016 and 2017 historical data as a foundation for its growth prediction for the industry from 2019 to 2026, with 2018 acting as the base year.
An anti-cancer medicine known as crizotinib is sold under the brand name Xalkori. The enzyme anaplastic lymphoma kinase (ALK) and the oncogene c-ros are both inhibited, which is how it operates. In certain countries, crizotinib is approved for the treatment of specific cases of non-small cell lung cancer (NSCLC). Clinical trials are now evaluating its efficacy and safety in treating various advanced malignancies in both adults and children. There has been little development in the crizotinib market thus far.
The focused approach of crizotinib in treating specific types of cancer, particularly non-small cell lung cancer (NSCLC) with ALK genetic alterations, boosts the crizotinib market. It improves treatment outcomes by blocking key proteins that promote cancer cell growth. The fact that crizotinib is still being studied and tried out for potential new uses also adds to its appeal. The expansion of this treatment's potential patient base is being propelled by developments in precision medicine and genetic testing.
If other targeted therapies or treatments for the same genetic alterations were to emerge, it might limit the Crizotinib market. The demand for Crizotinib may be impacted by the introduction of new pharmaceuticals or treatment modalities that provide patients competitive alternatives as medical research advances. Market expansion can also be hindered by regulatory hurdles and the high costs of developing and distributing targeted medications, such as Crizotinib. This may limit the number of patients who are able to use it.
The increasing knowledge of the genetic abnormalities that cause particular forms of cancer presents a fantastic opportunity for the Crizotinib business. Targeted medicines, such as Crizotinib, are becoming more important in the era of precision medicine for the efficient treatment of patients with certain genetic abnormalities. Pharmaceutical companies have a great chance to increase their investment in Crizotinib research, development, and distribution because of this. This has the ability to increase its applicability and improve outcomes for a broader spectrum of cancer patients. Crizotinib is a specialized medicine that is projected to continue growing in demand as healthcare systems throughout the world prioritize tailored treatment options. This bodes well for the market for this treatment.
Report Coverage
Global Crizotinib research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Crizotinib report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Crizotinib competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Crizotinib market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Crizotinib market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Crizotinib market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Pfizer, Bulat Pharmaceutical, Beacon Pharmaceuticals PLC, Selleck Chemicals, Incepta Pharmaceuticals Ltd, Shanghai Hope-Chem Co.,Ltd ,WUHAN HANWAYS PHARMCHEM CO., LTD., DEAFARMA, Apothecon Pharmaceuticals Pvt Ltd., LGM Pharma, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd, MANUS AKTTEVA BIOPHARMA LLP, Vea Impex (I) Pvt. Ltd
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Crizotinib market based on the below-mentioned segments:
Global Crizotinib Market, By Type
250mg-60 Capsules
200mg-60 Capsules
250mg-28 Capsules
Global Crizotinib market, By Application
ALK Positive NSCLC
ROS1 Positive NSCLC
Global Crizotinib market, Regional Analysis
For the treatment of non-small cell lung cancer (NSCLC), clinicians often prescribe crizotinib, a cancer drug. Because it inhibits the proliferation of tumor cells, this medication reduces the progression of cancer. Because it inhibits the proliferation of cancer cells, the medicine crizotinib is also known as an antineoplastic agent. Ultimately, the body eliminates these cancer cells. One class of targeted therapeutic medications called cancer growth inhibitors includes this substance, which is a tyrosine kinase receptor inhibitor. If the NSCLC exhibits alterations in a gene arrangement known as ALK-positive and ROS1-positive, it can be utilized. Cristopinib also prevents the proliferation of harmful cancer cells by preventing the expression of genes that code for malignancy.
Crisetinib is a medication that fights cancer. Patients with persistent non-small cell lung cancer can now take this medication thanks to the approval of the US regulatory agency. By inhibiting the proliferation of harmful cancer cells, crizotinib aims to halt the progression of deadly diseases. Inhibiting cancerous gene rearrangement is the primary goal of this drug's administration to patients, rather than providing a full cure. As long as crizotinib is effective and the medication is not causing any undesirable side effects, it is often administered at home according to a doctor's prescription. One major element propelling crizotinib's global market expansion is the drug's superior efficacy in treating non-small cell lung cancer.
This Crizotinib market research report analyzes the industry's size, sales, demand, growth, gross profit, and profitability in great detail. Using an analysis of the collected data, it predicts what might happen in the industry over the next several years. This study used 2016 and 2017 historical data as a foundation for its growth prediction for the industry from 2019 to 2026, with 2018 acting as the base year.
An anti-cancer medicine known as crizotinib is sold under the brand name Xalkori. The enzyme anaplastic lymphoma kinase (ALK) and the oncogene c-ros are both inhibited, which is how it operates. In certain countries, crizotinib is approved for the treatment of specific cases of non-small cell lung cancer (NSCLC). Clinical trials are now evaluating its efficacy and safety in treating various advanced malignancies in both adults and children. There has been little development in the crizotinib market thus far.
The focused approach of crizotinib in treating specific types of cancer, particularly non-small cell lung cancer (NSCLC) with ALK genetic alterations, boosts the crizotinib market. It improves treatment outcomes by blocking key proteins that promote cancer cell growth. The fact that crizotinib is still being studied and tried out for potential new uses also adds to its appeal. The expansion of this treatment's potential patient base is being propelled by developments in precision medicine and genetic testing.
If other targeted therapies or treatments for the same genetic alterations were to emerge, it might limit the Crizotinib market. The demand for Crizotinib may be impacted by the introduction of new pharmaceuticals or treatment modalities that provide patients competitive alternatives as medical research advances. Market expansion can also be hindered by regulatory hurdles and the high costs of developing and distributing targeted medications, such as Crizotinib. This may limit the number of patients who are able to use it.
The increasing knowledge of the genetic abnormalities that cause particular forms of cancer presents a fantastic opportunity for the Crizotinib business. Targeted medicines, such as Crizotinib, are becoming more important in the era of precision medicine for the efficient treatment of patients with certain genetic abnormalities. Pharmaceutical companies have a great chance to increase their investment in Crizotinib research, development, and distribution because of this. This has the ability to increase its applicability and improve outcomes for a broader spectrum of cancer patients. Crizotinib is a specialized medicine that is projected to continue growing in demand as healthcare systems throughout the world prioritize tailored treatment options. This bodes well for the market for this treatment.
Report Coverage
Global Crizotinib research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Crizotinib report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Crizotinib competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Crizotinib market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2031 |
| Base Year | 2023 |
| Forecast Period | 2023-2031 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Pfizer, Bulat Pharmaceutical, Beacon Pharmaceuticals PLC, Selleck Chemicals, Incepta Pharmaceuticals Ltd, Shanghai Hope-Chem Co.,Ltd ,WUHAN HANWAYS PHARMCHEM CO., LTD., DEAFARMA, Apothecon Pharmaceuticals Pvt Ltd., LGM Pharma, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd, MANUS AKTTEVA BIOPHARMA LLP, Vea Impex (I) Pvt. Ltd |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Crizotinib Market from 2021 to 2031.
- Market Forecast for Crizotinib Market from 2021 to 2031.
- Regional Market Share and Revenue from 2021 to 2031.
- Country Market share within region from 2021 to 2031.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Crizotinib competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Crizotinib
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Crizotinib market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Crizotinib market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Pfizer, Bulat Pharmaceutical, Beacon Pharmaceuticals PLC, Selleck Chemicals, Incepta Pharmaceuticals Ltd, Shanghai Hope-Chem Co.,Ltd ,WUHAN HANWAYS PHARMCHEM CO., LTD., DEAFARMA, Apothecon Pharmaceuticals Pvt Ltd., LGM Pharma, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd, MANUS AKTTEVA BIOPHARMA LLP, Vea Impex (I) Pvt. Ltd
Primary Target Market
- Market Players of Crizotinib
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Crizotinib market based on the below-mentioned segments:
Global Crizotinib Market, By Type
250mg-60 Capsules
200mg-60 Capsules
250mg-28 Capsules
Global Crizotinib market, By Application
ALK Positive NSCLC
ROS1 Positive NSCLC
Global Crizotinib market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive crizotinib market market research and competitor analysis for your business to help you develop more profound insights into the crizotinib market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the crizotinib market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.